XBIO (Xenetic Biosciences) Cyclically Adjusted Book per Share: $73.48 (As of Mar. 2026)


XBIO Xenetic Biosciences Inc XBIO
79 GF Score
Price $2.74
GF Value $4.20
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences Cyclically Adjusted Book per Share?

Xenetic Biosciences XBIO -1.44% 79 Cyclically Adjusted Book per Share is $73.48 as of Mar. 2026. GuruFocus rates XBIO with a GF Score™ of 79/100 and a GF Value™ of $4.20 (Possible Value Trap). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Xenetic Biosciences's adjusted book value per share for the three months ended in Mar. 2026 was $3.034. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $73.48 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Xenetic Biosciences's average Cyclically Adjusted Book Growth Rate was -20.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Xenetic Biosciences was -8.40% per year. The lowest was -18.60% per year. And the median was -13.50% per year.

As of today (2026-07-12), Xenetic Biosciences's current stock price is $2.735. Xenetic Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $73.48. Xenetic Biosciences's Cyclically Adjusted PB Ratio of today is 0.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Xenetic Biosciences was 0.32. The lowest was 0.02. And the median was 0.03.


Xenetic Biosciences  (NAS:XBIO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Xenetic Biosciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.735/73.48
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Xenetic Biosciences was 0.32. The lowest was 0.02. And the median was 0.03.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Xenetic Biosciences Cyclically Adjusted Book per Share Related Terms


Xenetic Biosciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Xenetic Biosciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences Cyclically Adjusted Book per Share Chart

Xenetic Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 129.37 141.98 154.56 99.28 76.56

Xenetic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.74 87.02 82.63 76.56 73.48

XBIO vs ACXP, SILO, GOVX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Xenetic Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's Cyclically Adjusted PB Ratio falls into.


XBIO
79GF Score
Xenetic Biosciences Inc XBIO
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenetic Biosciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xenetic Biosciences's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.034/330.2130*330.2130
=3.034

Current CPI (Mar. 2026) = 330.2130.

Xenetic Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201606 85.493 241.018 117.132
201609 86.275 241.428 118.003
201612 230.943 241.432 315.867
201703 193.069 243.801 261.500
201706 157.616 244.955 212.475
201709 130.849 246.819 175.060
201712 195.863 246.524 262.354
201803 176.479 249.554 233.519
201806 163.872 251.989 214.742
201809 144.782 252.439 189.388
201812 127.051 251.233 166.992
201903 132.368 254.202 171.948
201906 112.913 256.143 145.565
201909 32.426 256.759 41.702
201912 28.353 256.974 36.434
202003 25.790 258.115 32.994
202006 24.373 257.797 31.219
202009 12.548 260.280 15.919
202012 13.958 260.474 17.695
202103 12.506 264.877 15.591
202106 11.367 271.696 13.815
202109 15.057 274.310 18.126
202112 13.684 278.802 16.207
202203 12.587 287.504 14.457
202206 10.605 296.311 11.818
202209 10.139 296.808 11.280
202212 8.994 296.797 10.007
202303 8.475 301.836 9.272
202306 7.746 305.109 8.383
202309 7.104 307.789 7.622
202312 6.356 306.746 6.842
202403 5.630 312.332 5.952
202406 4.831 314.175 5.078
202409 4.562 315.301 4.778
202412 3.894 315.605 4.074
202503 3.321 319.799 3.429
202506 2.885 322.561 2.953
202509 2.564 324.800 2.607
202512 3.228 324.054 3.289
202603 3.034 330.213 3.034

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $73.48 mean?
Xenetic Biosciences (XBIO) has a Cyclically Adjusted Book per Share of $73.48 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Xenetic Biosciences and its competitors.
Is Xenetic Biosciences' Cyclically Adjusted Book per Share too high?
Xenetic Biosciences' current Cyclically Adjusted Book per Share is $73.48. Overall, Xenetic Biosciences has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Cyclically Adjusted Book per Share compare to ACXP and SILO?
Xenetic Biosciences' Cyclically Adjusted Book per Share of $73.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current Cyclically Adjusted Book per Share is $73.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.20, compared to a current price of $2.74 — trading 34.9% below its estimated fair value. The current Cyclically Adjusted Book per Share is $73.48. Xenetic Biosciences' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Cyclically Adjusted Book per Share is $73.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of $2.74 is trading 34.9% below its estimated GF Value™ of $4.20. GuruFocus considers Xenetic Biosciences to be Possible Value Trap.

Key valuation signals for XBIO:

  • Cyclically Adjusted Book per Share: $73.48
  • GF Value™: $4.20 vs. price of $2.74 (34.9% below fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xenetic Biosciences Business Description

Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
79GF Score

Get the complete analysis for XBIO

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price
$4.20
GF Value